))
Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD
Manage episode 455992613 series 3381434
İçerik ReachMD tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan ReachMD veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
CME credits: 1.25
Valid until: 15-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
…
continue reading
Valid until: 15-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
454 bölüm
Paylaş
